CD274 and triple-negative breast carcinoma: Avelumab significantly improved NK cell-mediated cytotoxicity against triple-negative breast cancer cells and tumor cells expressing higher levels of PD-L1 were shown to be more sensitive to avelumab-mediated ADCC.